ImmuneID employs a proprietary, massively parallel platform that leverages next-generation sequencing, robotic automation and artificial intelligence to identify and therapeutically target millions of antibody interactions. The company is developing precision immunology therapeutics across autoimmunity, severe allergy, oncology and infectious disease and plans to use new financing to advance those therapeutic candidates. The platform and its applications have been featured in Science and published in Cell, PNAS and Nature Communications, and trace to technology developed by scientific founders Stephen Elledge, Ben Larman and Tomasz Kula. ImmuneID was founded in 2020 by Longwood Fund and is headquartered in Cambridge, MA. David Donabedian, Ph.D., serves as CEO and the company highlights experienced scientific and industry leadership, including co-founder and SAB chair Stephen Elledge, a Lasker Award winner. Financially, the company has raised over $70 million since its December 2020 launch, including a $22 million seed round led by Longwood Fund and the new Series A described below. ImmuneID is a precision immunology company employing a proprietary platform to identify and therapeutically target millions of antibody interactions that drive immune diseases. Its platform, including VirScan, combines next-generation sequencing, robotic automation, and artificial intelligence to provide massively parallel, multiplexed, and unbiased profiling of human immune responses. The company traces its technology to founders Stephen Elledge, Ben Larman, and Tomasz Kula and cites multiple validations including publications in Science and Cell. ImmuneID plans to use its platform to develop therapeutic programs in severe allergy, autoimmunity, oncology, and infectious disease and to generate real-time insights into public health risks. The company was founded in 2020 and is headquartered in Cambridge, MA. It announced a $17M financing to advance those therapeutic programs.

Total raised

$67M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2021